A Conjugation Strategy to Modulate Antigen Binding and FcRn Interaction Leads to Improved Tumor Targeting and Radioimmunotherapy Efficacy with an Antibody Targeting Prostate-Specific Antigen

Oskar Vilhelmsson Timmermand; Anders Örbom; Mohamed Altai; Wahed Zedan; Bo Holmqvist; Marcella Safi; Thuy A Tran; Sven-Erik Strand; Joanna Strand

doi:10.3390/cancers13143469

A Conjugation Strategy to Modulate Antigen Binding and FcRn Interaction Leads to Improved Tumor Targeting and Radioimmunotherapy Efficacy with an Antibody Targeting Prostate-Specific Antigen

Cancers (Basel). 2021 Jul 11;13(14):3469. doi: 10.3390/cancers13143469.

Authors

Affiliations

¹ Department of Clinical Sciences Lund, Oncology, Lund University, 22243 Lund, Sweden.
² ImaGene-iT AB, Medicon Village, 22363 Lund, Sweden.
³ Department of Radiopharmacy, Karolinska University Hospital, 17177 Stockholm, Sweden.
⁴ Department of Clinical Sciences Lund, Medical Radiation Physics, Lund University, 22243 Lund, Sweden.
⁵ Department of Clinical Oncology, Skane University Hospital, 22243 Lund, Sweden.

Abstract

Background: The humanized monoclonal antibody (mAb) hu5A10 specifically targets and internalizes prostate cancer cells by binding to prostate specific antigen (PSA). Preclinical evaluations have shown that hu5A10 is an excellent vehicle for prostate cancer (PCa) radiotheranostics. We studied the impact of different chelates and conjugation ratios on hu5A10's target affinity, neonatal fc-receptor interaction on in vivo targeting efficacy, and possible enhanced therapeutic efficacy.

Methods: In our experiment, humanized 5A10 (hu5A10) was conjugated with DOTA or DTPA at a molar ratio of 3:1, 6:1, and 12:1. Surface plasmon resonance (SPR) was used to study antigen and FcRn binding to the antibody conjugates. [¹¹¹In]hu5A10 radio-immunoconjugates were administered intravenously into BALB/c mice carrying subcutaneous LNCaP xenografts. Serial Single-photon emission computed tomography (SPECT) images were obtained during the first week. Tumors were harvested and radionuclide distribution was analyzed by autoradiography along with microanatomy and immunohistochemistry.

Results: As seen by SPR, the binding to PSA was clearly affected by the chelate-to-antibody ratio. Similarly, FcRn (neonatal fc-receptor) interacted less with antibodies conjugated at high ratios of chelator, which was more pronounced for DOTA conjugates. The autoradiography data indicated a higher distribution of radioactivity to the rim of the tumor for lower ratios and a more homogenous distribution at higher ratios. Mice injected with ratio 3:1 ¹¹¹In-DOTA-hu5A10 showed no significant difference in tumor volume when compared to mice given vehicle over a time period of 3 weeks. Mice given a similar injection of ratio 6:1 ¹¹¹In-DOTA-hu5A10 or 6:1 ¹¹¹In-DTPA-hu5A10 or 12:1 ¹¹¹In-DTPA-hu5A10 showed significant tumor growth retardation. Conclusions: The present study demonstrated that the radiolabeling strategy could positively modify the hu5A10's capacity to bind PSA and complex with the FcRn-receptor, which resulted in more homogenous activity distribution in tumors and enhanced therapy efficacy.

Keywords: FcRn; PSA; hu5A10; prostate cancer; radionuclide therapy.

Abstract

Grants and funding